Journey Medical Corp Enters Material Definitive Agreement
Ticker: DERM · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1867066
Sentiment: neutral
Topics: material-agreement, financial-obligation, 8-k
Related Tickers: JMEI
TL;DR
JMEI signed a new deal, likely involving debt or a major financial commitment.
AI Summary
On September 25, 2025, Journey Medical Corporation entered into a material definitive agreement related to a direct financial obligation. The company, incorporated in Delaware with its principal executive offices in Scottsdale, AZ, filed this 8-K report on September 26, 2025.
Why It Matters
This filing indicates Journey Medical Corp has entered into a significant financial agreement, which could impact its financial obligations and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements, especially those involving financial obligations, can introduce financial risks and operational changes for the company.
Key Numbers
- 001-41063 — Commission File Number (Identifies the company's SEC filing history.)
- 47-1879539 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Journey Medical Corporation (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
- September 26, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Scottsdale, AZ (location) — Principal Executive Offices
FAQ
What type of material definitive agreement did Journey Medical Corporation enter into?
The filing states the company entered into a material definitive agreement related to a direct financial obligation or an obligation under an off-balance sheet arrangement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 25, 2025.
What is Journey Medical Corporation's principal executive office address?
The principal executive offices are located at 9237 E Via de Ventura Blvd., Suite 105, Scottsdale, AZ 85258.
In which state is Journey Medical Corporation incorporated?
Journey Medical Corporation is incorporated in Delaware.
What is the company's telephone number?
The company's telephone number is (480) 434-6670.
Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-09-26 16:39:02
Key Financial Figures
- $25.0 million — ity in the original principal amount of $25.0 million. As of the date of this report, the Com
- $25.0 m — report, the Company has drawn the full $25.0 million, which is treated under the Amend
- $60.0 million — ing twelve-month basis, is greater than $60.0 million as of December 31, 2025 (revised from $
- $70.0 million — n as of December 31, 2025 (revised from $70.0 million), principal repayment is not required u
Filing Documents
- tm2527082d1_8k.htm (8-K) — 26KB
- 0001104659-25-093891.txt ( ) — 190KB
- derm-20250925.xsd (EX-101.SCH) — 3KB
- derm-20250925_lab.xml (EX-101.LAB) — 33KB
- derm-20250925_pre.xml (EX-101.PRE) — 22KB
- tm2527082d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. On September 25, 2025, Journey Medical Corporation (the "Company") entered into a Third Amendment to Credit Agreement (the "Third Amendment"), which amends that certain Credit Agreement, dated December 27, 2023 (the "Original Closing Date"), by and among the Company and SWK Funding LLC, and the other the financial institutions party thereto from time to time, as lenders (as amended by that certain First Amendment to Credit Agreement dated July 9, 2024, the Second Amendment to Credit Agreement dated October 21, 2024 and the Third Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a term loan facility in the original principal amount of $25.0 million. As of the date of this report, the Company has drawn the full $25.0 million, which is treated under the Amended Credit Agreement as a single loan (the "Term Loan"). The Third Amendment (i) extends the maturity date of the Term Loan from December 27, 2027 to June 27, 2028 and (ii) amends certain terms of the Revenue Based Payment Amount (as defined in the Amended Credit Agreement) affecting when repayments of principal will commence, and how quickly the principal amount of the Term Loan will be reduced prior to the maturity date. Under the Amended Credit Agreement, the Term Loan matures on June 27, 2028 unless the facility is otherwise terminated pursuant to the terms of the Amended Credit Agreement. Beginning in February 2026, the Company is required to repay the outstanding principal of the Term Loan quarterly in an amount equal to 7.5% of the principal amount of funded Term Loan. However, if the total revenue of the Company, measured on a trailing twelve-month basis, is greater than $60.0 million as of December 31, 2025 (revised from $70.0 million), principal repayment is not required until February 2027, at which point the Company is required to repay the outstanding principal of the Term Loan quarterly in an amount equal t
03
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosures set forth in Item 1.01 of this Current Report on Form 8-K are incorporated by reference herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Journey Medical Corporation (Registrant) Date: September 26, 2025 By: /s/ Claude Maraoui Claude Maraoui President and Chief Executive Officer